These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 25689936

  • 1. Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan.
    Sakaida I, Nakajima K, Okita K, Hori M, Izumi T, Sakurai M, Shibasaki Y, Tachikawa S, Tsubouchi H, Oka H, Kobayashi H.
    J Gastroenterol; 2015 Oct; 50(10):1047-53. PubMed ID: 25689936
    [Abstract] [Full Text] [Related]

  • 2. Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis.
    Sakaida I, Terai S, Nakajima K, Shibasaki Y, Tachikawa S, Tsubouchi H.
    J Gastroenterol; 2017 Feb; 52(2):229-236. PubMed ID: 27379386
    [Abstract] [Full Text] [Related]

  • 3. Tolvaptan for the treatment of liver cirrhosis oedema.
    Sakaida I.
    Expert Rev Gastroenterol Hepatol; 2014 Jul; 8(5):461-70. PubMed ID: 24678622
    [Abstract] [Full Text] [Related]

  • 4. The pharmacokinetics and pharmacodynamics of tolvaptan in patients with liver cirrhosis with insufficient response to conventional diuretics: a multicentre, double-blind, parallel-group, phase III study.
    Sakaida I, Yanase M, Kobayashi Y, Yasutake T, Okada M, Okita K, ASCITES Clinical Pharmacology Group.
    J Int Med Res; 2012 Jul; 40(6):2381-93. PubMed ID: 23321196
    [Abstract] [Full Text] [Related]

  • 5. The Efficacy of Tolvaptan in Congestive Heart Failure Patients with and Without Hypoalbuminemia: A Pilot Study.
    Okabe T, Yakushiji T, Igawa W, Ono M, Kido T, Ebara S, Yamashita K, Yamamoto MH, Saito S, Hoshimoto K, Amemiya K, Isomura N, Araki H, Ochiai M.
    Cardiovasc Ther; 2015 Oct; 33(5):275-81. PubMed ID: 26122275
    [Abstract] [Full Text] [Related]

  • 6. Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia.
    Hayashi M, Abe K, Fujita M, Okai K, Takahashi A, Ohira H.
    Intern Med; 2018 Sep 01; 57(17):2451-2458. PubMed ID: 29607963
    [Abstract] [Full Text] [Related]

  • 7. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia.
    Wang S, Zhang X, Han T, Xie W, Li Y, Ma H, Liebe R, Weng H, Ding HG.
    BMC Gastroenterol; 2018 Sep 04; 18(1):137. PubMed ID: 30180806
    [Abstract] [Full Text] [Related]

  • 8. Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio.
    Komiyama Y, Kurosaki M, Nakanishi H, Takahashi Y, Itakura J, Yasui Y, Tamaki N, Takada H, Higuchi M, Gotou T, Kubota Y, Takaura K, Hayashi T, Oh W, Okada M, Enomoto N, Izumi N.
    PLoS One; 2017 Sep 04; 12(3):e0174649. PubMed ID: 28362879
    [Abstract] [Full Text] [Related]

  • 9. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
    Nemerovski C, Hutchinson DJ.
    Clin Ther; 2010 Jun 04; 32(6):1015-32. PubMed ID: 20637957
    [Abstract] [Full Text] [Related]

  • 10. Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis.
    Tajiri K, Tokimitsu Y, Ito H, Atarashi Y, Kawai K, Minemura M, Yasumura S, Takahara T, Shimizu Y, Sugiyama T.
    Dig Dis; 2018 Jun 04; 36(4):314-321. PubMed ID: 29852495
    [Abstract] [Full Text] [Related]

  • 11. Limited Efficacy of Tolvaptan in Patients with Cirrhosis and Severe Hyponatremia: Real-Life Experience.
    Pose E, Solà E, Piano S, Gola E, Graupera I, Guevara M, Cárdenas A, Angeli P, Ginès P.
    Am J Med; 2017 Mar 04; 130(3):372-375. PubMed ID: 27746291
    [Abstract] [Full Text] [Related]

  • 12. Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo-controlled phase 2 trial.
    Wang YF, Tang JT, Han T, Ding HG, Ye WJ, Wang MR, Cheng J, Yang YP, Chen CW, Xie Q, Mao Q, Niu JQ, Wang ZH, Wei Z, Chen YX, Zeng M, Mao YM.
    J Dig Dis; 2018 Mar 04; 19(3):144-154. PubMed ID: 29389068
    [Abstract] [Full Text] [Related]

  • 13. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients.
    Zhang X, Wang SZ, Zheng JF, Zhao WM, Li P, Fan CL, Li B, Dong PL, Li L, Ding HG.
    World J Gastroenterol; 2014 Aug 28; 20(32):11400-5. PubMed ID: 25170228
    [Abstract] [Full Text] [Related]

  • 14. The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan.
    Kogiso T, Kobayashi M, Yamamoto K, Ikarashi Y, Kodama K, Taniai M, Torii N, Hashimoto E, Tokushige K.
    Intern Med; 2017 Nov 15; 56(22):2993-3001. PubMed ID: 28943585
    [Abstract] [Full Text] [Related]

  • 15. Urine osmolarity predicts the body weight-reduction response to tolvaptan in chronic kidney disease patients: a retrospective, observational study.
    Iwatani H, Kawabata H, Sakaguchi Y, Yamamoto R, Hamano T, Rakugi H, Isaka Y.
    Nephron; 2015 Nov 15; 130(1):8-12. PubMed ID: 25926290
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema.
    Sakaida I, Yamashita S, Kobayashi T, Komatsu M, Sakai T, Komorizono Y, Okada M, Okita K, ASCITES 14-Day Administration Study Group.
    J Int Med Res; 2013 Jun 15; 41(3):835-47. PubMed ID: 23685892
    [Abstract] [Full Text] [Related]

  • 17. Effects of tolvaptan on urine output in hospitalized heart failure patients with hypoalbuminemia or proteinuria.
    Takagi K, Sato N, Ishihara S, Sone M, Tokuyama H, Nakama K, Omote T, Kikuchi A, Ishikawa M, Amitani K, Takahashi N, Maruyama Y, Imura H, Shimizu W.
    Heart Vessels; 2018 Apr 15; 33(4):413-420. PubMed ID: 29063302
    [Abstract] [Full Text] [Related]

  • 18. Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial.
    Tang J, Wang Y, Han T, Mao Q, Cheng J, Ding H, Shang J, Zhang Q, Niu J, Ji F, Chen C, Jia J, Jiang X, Lv N, Gao Y, Wang Z, Wei Z, Chen Y, Zeng M, Mao Y.
    BMC Gastroenterol; 2020 Nov 19; 20(1):391. PubMed ID: 33213378
    [Abstract] [Full Text] [Related]

  • 19. Plasma concentration and efficacy of tolvaptan in cirrhotic patients with refractory ascites.
    Sagawa E, Okubo H, Ando H, Sorin Y, Kanazawa R, Nakadera E, Fukada H, Kokubu S, Miyazaki A.
    J Pharmacol Sci; 2019 Apr 19; 139(4):373-376. PubMed ID: 30857764
    [Abstract] [Full Text] [Related]

  • 20. Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites.
    Goto A, Terai S, Nakamura M, Matsumoto M, Sakaida I.
    Clin J Gastroenterol; 2015 Feb 19; 8(1):47-51. PubMed ID: 25475138
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.